Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress

Core Insights - Madrigal Pharmaceuticals is set to present significant data on resmetirom at the EASL Congress, highlighting its potential to improve liver health in patients with compensated MASH cirrhosis [1][3] - The company is preparing for a European Commission decision regarding the marketing authorization application for resmetirom, with expectations to launch in Germany in the second half of 2025 [2] Company Overview - Madrigal Pharmaceuticals focuses on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need [14] - Resmetirom is the first approved medication for MASH in the U.S., targeting key underlying causes of the disease [1][14] Clinical Data and Presentations - The late-breaking oral presentation at EASL will detail two-year data from the Phase 3 MAESTRO-NAFLD-1 trial, showing improvements in liver stiffness and fibrosis biomarkers in 122 patients [1][3] - Additional posters will cover various aspects of MASH, including baseline characteristics and the use of noninvasive tests for diagnosis [3] Market Context - An estimated 1.5 million patients in the U.S. have been diagnosed with MASH, with a focus on reaching approximately 315,000 patients with moderate to advanced fibrosis [7] - MASH is projected to become the leading cause of liver transplantation in the U.S., emphasizing the urgency for effective treatments [5][6]